| Age, years ±SD |
81 ±6 |
80 ±6 |
0.54 |
| Male, n (%) |
7 (58) |
7 (44) |
0.70 |
| Body mass index, kg/m2 ±SD |
25.3 ±4.5 |
25.9 ±5.5 |
0.76 |
| Log EuroSCORE, % ±SD |
23.6 ±18.6 |
24.4 ±18.0 |
0.91 |
| STS score: mortality, % ±SD |
7.1 ±5.4 |
7.8 ±8.0 |
0.81 |
| STS score: permanent stroke, % ±SD |
2.5 ±1.0 |
3.4 ±2.2 |
0.23 |
| Peak-to-peak gradient, mmHg ±SD |
40.3 ±22.8 |
54.4 ±20.7 |
0.10 |
| Ejection fraction, % ±SD |
50.0 ±15.2 |
48.4 ±15.5 |
0.78 |
| NYHA class ±SD |
2.9 ±0.3 |
2.9 ±0.7 |
0.92 |
| Minimental state examination score BL |
27.1 ±2.7 |
26.2 ±3.0 |
0.43 |
| Minimental state examination score FU 2 |
25.7 ±0.3 |
27.7 ±1.9 |
0.17 |
| Comorbidities |
|
|
|
| Hypertension, n (%) |
11 (92) |
15 (94) |
1.00 |
| Diabetes, n (%) |
1 (8) |
3 (19) |
0.61 |
| Smoking, n (%) |
2 (17) |
4 (25) |
0.67 |
| Dyslipidemia, n (%) |
8 (67) |
9 (56) |
0.71 |
| Creatinine, mg/dl ±SD |
1.1 ±0.2 |
1.2 ±0.6 |
0.49 |
| Glomerular fibrilation rate, ml/min ±SD |
59.7 ±8.7 |
56.5 ±15.1 |
0.52 |
| Hemodialysis, n (%) |
0 (0) |
0 (0) |
- |
| Atrial fibrillation or flutter, n (%) |
3 (25) |
5 (31) |
1.00 |
| CHADS2-Score ±SD |
2.3 ±0.8 |
2.8 ±1.4 |
0.27 |
| Prior stroke or TIA, n (%) |
1 (8) |
6 (38) |
0.18 |
| PVD, n (%) |
3 (25) |
7 (44) |
0.43 |
| Coronary artery disease, n (%) |
5 (42) |
9 (56) |
0.70 |
| Prior myocarial infarction, n (%) |
3 (25) |
1 (6) |
0.29 |
| Prior PCI, n (%) |
2 (17) |
6 (38) |
0.40 |
| Prior CABG, n (%) |
1 (8) |
0 (0) |
0.43 |
| Procedural characteristics |
|
|
|
| Procedure time, min ±SD |
79.1 ±33.2 |
111.6 ±63.1 |
0.12 |
| Direct TAVI without predilatation, n (%) |
3 (25) |
5 (31) |
1.00 |
| Corevalve 23/26/29/31 mm, n |
0/4/5/2 |
0/5/7/0 |
-/1.00/1.00/0.18 |
| Edwards-Sapien 23/26 mm, n |
0/0 |
2/1 |
0.49/1.0 |
| Symetis 23 mm, n |
1 |
1 |
1.00 |
| Post-dilatation, n (%) |
1 (8) |
6 (38) |
0.18 |
| Rapid pacing runs, n (%) |
0.9 ±0.7 |
1.2 ±1.2 |
0.50 |
| Post-procedural characteristics |
|
|
|
| SIRS, n (%) |
3 (25) |
5 (31) |
1.00 |
| Minor bleeding, n (%) |
2 (17) |
8 (50) |
0.11 |
| Major bleeding, n (%) |
0 (0) |
1 (6) |
1.00 |
| Stroke, n (%) |
0 (0) |
0 (0) |
- |
| Evidence of embolic events in DW-MRI, n(%) |
8 (67) |
9 (56) |
0.71 |
| Medication @FU2 |
|
|
|
| Acetylsalicylic acid, n (%) |
8 (67) |
13 (81) |
0.42 |
| Clopidogrel hydrogen sulphate, n (%) |
1 (8) |
2 (13) |
1.00 |
| Beta-blocker, n (%) |
10 (83) |
14 (88) |
1.00 |
| Statin, n (%) |
6 (50) |
11 (69) |
0.44 |
| AT1 antagonist, n (%) |
2 (17) |
7 (44) |
0.22 |
| ACE inibitor, n (%) |
7 (58) |
7 (44) |
0.70 |
| Diuretics, n (%) |
10 (83) |
12 (75) |
0.67 |
